Q4 Earnings Forecast for RYTM Issued By Leerink Partnrs

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Equities research analysts at Leerink Partnrs issued their Q4 2026 EPS estimates for Rhythm Pharmaceuticals in a note issued to investors on Sunday, July 13th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings per share of ($0.62) for the quarter. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Rhythm Pharmaceuticals' current full-year earnings is ($4.32) per share.

Several other analysts have also recently commented on the stock. Needham & Company LLC restated a "buy" rating and set a $95.00 price target (up from $72.00) on shares of Rhythm Pharmaceuticals in a report on Wednesday, July 9th. The Goldman Sachs Group began coverage on shares of Rhythm Pharmaceuticals in a research report on Thursday, July 10th. They set a "buy" rating and a $97.00 price objective on the stock. Guggenheim reaffirmed a "buy" rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, July 10th. Morgan Stanley set a $95.00 price objective on shares of Rhythm Pharmaceuticals and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Finally, Oppenheimer set a $110.00 price objective on shares of Rhythm Pharmaceuticals and gave the company an "outperform" rating in a research report on Thursday, July 10th. Fourteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $91.93.

Rhythm Pharmaceuticals Stock Performance

Shares of RYTM stock traded down $1.61 during trading on Tuesday, hitting $89.07. 332,105 shares of the company were exchanged, compared to its average volume of 588,437. The firm has a market capitalization of $5.67 billion, a price-to-earnings ratio of -31.69 and a beta of 2.26. The business's 50-day simple moving average is $66.50 and its 200 day simple moving average is $60.21. Rhythm Pharmaceuticals has a twelve month low of $40.61 and a twelve month high of $94.80.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.12). The company had revenue of $37.72 million for the quarter, compared to analyst estimates of $40.43 million. Rhythm Pharmaceuticals had a negative return on equity of 739.62% and a negative net margin of 123.26%. The business's revenue for the quarter was up 25.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.35) earnings per share.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. BI Asset Management Fondsmaeglerselskab A S bought a new position in Rhythm Pharmaceuticals during the first quarter worth $34,000. State of Wyoming bought a new position in Rhythm Pharmaceuticals during the fourth quarter worth $61,000. GF Fund Management CO. LTD. acquired a new stake in Rhythm Pharmaceuticals during the fourth quarter worth $72,000. CWM LLC boosted its stake in Rhythm Pharmaceuticals by 92.3% during the first quarter. CWM LLC now owns 2,584 shares of the company's stock worth $137,000 after buying an additional 1,240 shares in the last quarter. Finally, Bayforest Capital Ltd acquired a new stake in Rhythm Pharmaceuticals during the first quarter worth $166,000.

Insider Buying and Selling

In other news, EVP Yann Mazabraud sold 6,745 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Tuesday, April 29th. The shares were sold at an average price of $65.08, for a total value of $438,964.60. Following the transaction, the executive vice president owned 37,655 shares of the company's stock, valued at $2,450,587.40. This trade represents a 15.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Hunter C. Smith sold 42,120 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $80.48, for a total transaction of $3,389,817.60. Following the completion of the transaction, the chief financial officer directly owned 116,915 shares in the company, valued at approximately $9,409,319.20. This represents a 26.48% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 93,673 shares of company stock valued at $7,118,510. 6.10% of the stock is owned by corporate insiders.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.